Regeneron Pharmaceuticals, Inc. Price Today
Regeneron Pharmaceuticals, Inc.
REGN
Healthcare
$84.15B
💰
Market Cap
20.5
💸
Price to Earnings
$37.9
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
16 |
Strong Buy |
9 |
Hold |
7 |
Sell |
1 |
Strong Sell |
0 |
REGN Price Forecast Target
775.2 👉 1064.0 +37%
REGN EPS Forecast
37.9 👉 43.9 +16%
Financials
Profit Margin
34 %
Revenue Growth
10.5 %
Dividend
$ 0
Held Percent
2.5% - Insiders
89.4% - Institutions
8.1% - Public
Major Fund Holders
-
💰 FMR, LLC $6.6B
-
💰 Blackrock Inc. $6.5B
-
💰 Vanguard Group Inc $6.4B
-
💰 JP Morgan Chase & Company $4.7B
-
💰 Capital World Investors $4.0B
Stock Ideas
Ken Griffin Portfolio
Ken Griffin, the visionary founder of Citadel Investment Group, has transformed portfolio strategy with his innovative and tech-driven approach. Starting as a college student trading stock options, Griffin quickly rose to success and attracted signi…
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…
David Einhorn Portfolio
David Einhorn is one of the most successful long/short equity hedge fund managers of the past decade. As of July 2013, David Einhorn’s Greenlight Capital has returned 19.5% since its inception in 1996. Greenlight Capital’s market beta is around 0.5,…📮FAQ
Some Frequently Asked Questions.
The Regeneron Pharmaceuticals, Inc. industry is Biotechnology
The Regeneron Pharmaceuticals, Inc. sector is Healthcare
The Regeneron Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is 17.7
The Regeneron Pharmaceuticals, Inc. Price to Earnings PE ratio is 20.5
The Market Capitalization of Regeneron Pharmaceuticals, Inc. is $84.15B
There are total of 101357990 float shares with 89.4% held by Institutions and 2.5% held by insiders
The MRegeneron Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $43.9
The Regeneron Pharmaceuticals, Inc. Earnings per Share EPS is 37.9
The Regeneron Pharmaceuticals, Inc. company has $7020000000 gross profits with 34 profit margins
The Regeneron Pharmaceuticals, Inc. Earnings Growth is 0.138% with 0.136% quarterly earnings growth
The Regeneron Pharmaceuticals, Inc. Revenue is $12670799872 with 0.105 revenue growth
The price target for Regeneron Pharmaceuticals, Inc. stock is $1064.0 for the high target and $680.0 for the low target
The consensus analyst recommendations for Regeneron Pharmaceuticals, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Regeneron Pharmaceuticals, Inc. is Buy, with the following breakdown:
- Buy: 16
- Strong Buy: 9
- Hold: 7
- Sell: 1
- Strong Sell: 0
The Beta of Regeneron Pharmaceuticals, Inc. is 0.1
The dividend of Regeneron Pharmaceuticals, Inc. is $0
The dividend yield of Regeneron Pharmaceuticals, Inc. is 0.0078%
The biggest institutional and mutual fund holders of Regeneron Pharmaceuticals, Inc. stock are
- FMR, LLC
- Blackrock Inc.
- Vanguard Group Inc
- JP Morgan Chase & Company
The Regeneron Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0